UltraGreen.ai Secures Regulatory Approval for Verdye in Singapore, Accelerating Southeast Asia Growth Strategy

Singapore, 5 May 2026 – UltraGreen.ai Limited (SGX: ULG), a global leader in fluorescence-guided surgery and digital health solutions, has announced a significant regulatory milestone: approval of Verdye (indocyanine green for injection) in Singapore. This approval marks a major strategic advancement in the Company’s Southeast Asia expansion plan and is anticipated to have material implications for shareholder value, given Singapore’s status as a regional healthcare hub and reference market for innovation.

Key Highlights for Investors

• Strategic Market Entry: Singapore’s regulatory approval opens access to a high-value, influential healthcare market. Singapore is widely recognized as a center of clinical excellence and a trendsetter for medical adoption in Southeast Asia, which may accelerate further regional regulatory approvals and commercial adoption.
• Clinical and Commercial Momentum: Verdye’s entry into Singapore enhances UltraGreen.ai’s commercial portfolio in Southeast Asia and deepens partnerships with leading healthcare institutions. This supports the broader adoption of fluorescence-guided surgery—a rapidly growing field with applications in oncology, colorectal, reconstructive, and vascular surgery.
• Integrated Platform Scaling: The Company’s approach extends beyond pharmaceutical sales. UltraGreen.ai is building a comprehensive platform, integrating Verdye with compatible imaging hardware and AI-powered data solutions. This ecosystem-based model is designed to drive recurring product utilization and support long-term revenue growth.
• Proven Global Track Record: Verdye is now approved in 41 countries, while the IC-Flow™ imaging system is cleared in 45 markets, underscoring the Company’s expanding global footprint and regulatory execution strength.
• Recent Milestones: This Singapore approval closely follows UltraGreen.ai’s successful IPO and regulatory clearance for Verdye in the Philippines, demonstrating robust execution and momentum in the region.

Potential Shareholder Impact

• Revenue Growth Catalyst: The Singapore approval enables immediate commercialization efforts in a lucrative market, which could drive near-term revenue growth and recurring demand as procedural adoption increases.
• Competitive Positioning: With fluorescence-guided surgery quickly becoming standard-of-care across multiple specialties, UltraGreen.ai is well-positioned to capture market share, especially given Verdye’s established safety and efficacy profile.
• Regional Reference Effect: Singapore’s endorsement may influence broader regulatory acceptance and accelerate market entry across Southeast Asia, compounding growth opportunities.
• Integrated Value Proposition: The Company’s strategy to combine pharmaceuticals, imaging hardware, and AI for surgical decision support could result in higher procedural volumes and recurring product utilization, enhancing long-term shareholder value.
• Leadership Commentary: CEO Ravi Sajwan highlighted Singapore’s importance as a reference market and reaffirmed UltraGreen.ai’s commitment to supporting surgeons with proven, innovative fluorescence-guided solutions, which may further boost investor confidence.

About UltraGreen.ai

UltraGreen.ai Limited (SGX: ULG) is a global innovator in fluorescence-guided surgery, offering vertical AI tools for precision surgery through data-driven fluorescence imaging solutions. Its flagship indocyanine green (ICG) product, sold as IC-GREEN® in the United States and Verdye outside North America, is the most widely used fluorescence imaging agent worldwide. The Company’s integrated ecosystem empowers surgeons with real-time visualization and perfusion insights, supporting better clinical outcomes. UltraGreen.ai is headquartered in Singapore, with operations spanning the United States, Ireland, and offices across the Asia-Pacific region.

Conclusion

The regulatory approval of Verdye in Singapore is a clear, potentially price-sensitive milestone for UltraGreen.ai. It reinforces the Company’s strategic execution, strengthens its regional growth prospects, and offers tangible catalysts for revenue and market share expansion. Shareholders should monitor subsequent commercial deployments and regional adoption trends, as these could materially affect the Company’s valuation in the near and medium term.

Disclaimer: This article is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Investors should conduct their own due diligence or consult a licensed financial advisor before making investment decisions. The information herein is based on a company press release and may contain forward-looking statements subject to risks and uncertainties.

View ULTRAGREEN AI USD Historical chart here